Trevi Therapeutics (TRVI) executive compensation, 2026 proxy

Jennifer Good, President and Chief Executive Officer, was paid $3.9M in 2025, up 52% from $2.6M the year before.

Filed
April 21, 2026
Annual meeting
June 3, 2026
Pay year
2025
Named executives
3
CEO total pay
$3.9M+52% vs prior year
CEO 2025 Salary
$622,382Annual base salary paid
CEO 2025 Bonus
$343,750Discretionary cash bonus
CEO 2025 Option Awards
$2,968,260Grant date fair value

How Good was paid

$3.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary16%Bonus9%Option awards75%All other compensation0%

Named executive officers

ExecutiveTotal
Jennifer GoodPresident and Chief Executive Officer$3,944,892
James Cassella, Ph.D.Chief Development Officer$1,637,220
Farrell Simon, Pharm. D.Chief Commercial Officer$1,355,897

What changed and why

  • $2.6MCEO total compensation increased from $2,589,035 in 2024 to $3,944,892 in 2025.
  • $3MOption awards for the CEO rose to $2,968,260 in 2025 from $1,601,781 in 2024.
  • 100%The board established a corporate performance score of 100% for the 2025 bonus period.
  • Named executive officers were awarded discretionary annual cash bonuses based on performance goals.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.